If 1 in 4 patients eligible were to self-monitor, the NHS would save £62 million*
A simple self-monitoring test could reduce the risk of stroke by half in thousands of people who currently take warfarin to prevent blood clots. Better access to self-monitoring of international normalized ratio (INR) levels, which measures how long it takes blood to form a clot, could also lower mortality rates by nearly two fifths 1, reduce the number of complications.
Current estimates show that oral anticoagulation therapy for the management of stable patients costs the NHS around £409 million 3,4. Studies also show that if only one in four patients took up self-monitoring 2, this would save the NHS approximately £62 million per year*.
* This figure takes into account all secondary care costs, primary care costs and costs of the CoaguChek XS device and test strips.